Biweekly low-dose cisplatin and 5-fluorouracil combination chemotherapy for advanced gastrointestinal carcinoma

• Published in: Gan to kagaku ryoho Vol. 27; no. 6; p. 859
• Main Authors: Kamata, T, Morita, A, Nakamoto, A, Onishi, I, Takeda, T, Koyasaki, N, Kanno, M
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.06.2000
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - mortality; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Cisplatin - administration & dosage; Colonic Neoplasms - drug therapy; Colonic Neoplasms - mortality; Drug Administration Schedule; Fluorouracil - administration & dosage; Gallbladder Neoplasms - drug therapy; Gallbladder Neoplasms - mortality; Humans; Lymphatic Metastasis; Middle Aged; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - mortality; Prognosis; Stomach Neoplasms - drug therapy; Stomach Neoplasms - mortality; Survival Rate
• ISSN: 0385-0684

Biweekly intravenous infusions of low-dose cisplatin (CDDP) and 5-fluorouracil (5-FU) were evaluated in 80 patients with advanced or recurrent gastric, colorectal, pancreatic or gallbladder adenocarcinoma. CDDP was given biweekly at a dose of 15 mg/m2 infused for 30 minutes, and 5-FU 375 mg/m2 was infused for 2 hours as many times as possible. The response rate among patients with gastric cancer was 26%, colorectal cancer 10%, pancreatic cancer 7.7%, and gallbladder cancer 42.9%. The response rates were not so high, but the median survival time of patients with recurrent gastric cancer was 17.3 months, pancreatic cancer 6.7 months, and gallbladder cancer 10.7 months. A patient with unresected advanced pancreatic head cancer with liver and para-aortic lymph node metastases received this therapy 38 times, and lived for 54 months. No severe side effects occurred in any of these cases. Thus, this chemotherapy could well be effective for the outcome of cases of advanced gastrointestinal carcinoma.